Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Nataliya Chernyukhin"'
Autor:
Raquel Izumi, Simon Rule, Jeff P. Sharman, Richard R. Furman, John M. Pagel, Susan O'Brien, Priti Patel, John C. Byrd, Beth Christian, Tamara Lezhava, Peter Hillmen, Marshall Baek, Ahmed Hamdy, Jennifer R. Brown, Clare Sun, Martin J.S. Dyer, Michael Wang, Roger G. Owen, Deborah M. Stephens, Nataliya Chernyukhin, Wojciech Jurczak, Paolo Ghia, Matthew Streetly
Publikováno v:
Leukemia. 35(11)
Bruton tyrosine kinase (BTK) inhibition is an effective therapy for many B-cell malignancies. Acalabrutinib is a next-generation, potent, highly selective, covalent BTK inhibitor. To characterize acalabrutinib tolerability, we pooled safety data from
Autor:
Kiyoshi Matsunaga, Yuriko Igawa, Jin Y. Jin, Alexander Strasak, Sandhya Girish, Yuying Gao, Ihsan Nijem, Dan Lu, Nataliya Chernyukhin, Bei Wang, Michael T. Lu, Chunze Li
Publikováno v:
Cancer chemotherapy and pharmacology. 78(3)
Trastuzumab emtansine (T-DM1) is indicated for previously treated HER2-positive metastatic breast cancer. Ethnic sensitivity assessment of T-DM1 was conducted using data from eight clinical studies to ensure that the clinically recommended dose is ap
Autor:
Nataliya Chernyukhin, Tianling Chen, Stephen E. Spurgeon, Paul M. Barr, Ahmed Hamdy, Raquel Izumi, Jeff Porter Sharman, Mark Roschewski, Jason M. Melear, Elena Bibikova, Ming Yin, J. Greg Slatter, Stephen D. Smith, Susan O'Brien
Publikováno v:
Journal of Clinical Oncology. 36:7518-7518
7518Background: Acalabrutinib, a selective, covalent inhibitor of Bruton tyrosine kinase (BTK), was evaluated in combination with the PI3Kδ inhibitor ACP-319 in pts with R/R B-cell malignancies. Me...
Autor:
Nadia Harbeck, G. Thomas Budd, Ian E. Krop, Alice Elizabeth Guardino, Joel K. Greenson, Meghna Samant, Melanie Smitt, Nataliya Chernyukhin, Véronique Diéras
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 32(25)
Purpose The antibody–drug conjugate trastuzumab emtansine (T-DM1) combines the cytotoxic activity of DM1 with the human epidermal growth factor receptor 2 (HER2) –targeted, antitumor properties of trastuzumab. T-DM1 has shown activity in phase I
Autor:
Nataliya Chernyukhin, Consuelo Blosch, Debra Zack, Daniel J. Lovell, Carol A. Wallace, Peter McCroskery, Scott Stryker
Publikováno v:
Pediatric Rheumatology Online Journal
Pediatric Rheumatology Online Journal, Vol 8, Iss 1, p 18 (2010)
Pediatric Rheumatology Online Journal, Vol 8, Iss 1, p 18 (2010)
Background Concerns have been raised about a potential link between the use of TNF inhibitors and development of malignancy in the pediatric population. We examined the worldwide experience of etanercept use in pediatric patients and the occurrence o
Autor:
Diéras V; Véronique Diéras, Institut Curie, Paris, France; Nadia Harbeck, University of Munich, Munich, Germany; G. Thomas Budd, Cleveland Clinic, Lerner College of Medicine, Cleveland, OH; Joel K. Greenson, University of Michigan, Ann Arbor, MI; Ellie A. Guardino, Meghna Samant, Nataliya Chernyukhin, and Melanie C. Smitt, Genentech, South San Francisco, CA; and Ian E. Krop, Dana-Farber Cancer Institute, Boston, MA. veronique.dieras@curie.fr., Harbeck N; Véronique Diéras, Institut Curie, Paris, France; Nadia Harbeck, University of Munich, Munich, Germany; G. Thomas Budd, Cleveland Clinic, Lerner College of Medicine, Cleveland, OH; Joel K. Greenson, University of Michigan, Ann Arbor, MI; Ellie A. Guardino, Meghna Samant, Nataliya Chernyukhin, and Melanie C. Smitt, Genentech, South San Francisco, CA; and Ian E. Krop, Dana-Farber Cancer Institute, Boston, MA., Budd GT; Véronique Diéras, Institut Curie, Paris, France; Nadia Harbeck, University of Munich, Munich, Germany; G. Thomas Budd, Cleveland Clinic, Lerner College of Medicine, Cleveland, OH; Joel K. Greenson, University of Michigan, Ann Arbor, MI; Ellie A. Guardino, Meghna Samant, Nataliya Chernyukhin, and Melanie C. Smitt, Genentech, South San Francisco, CA; and Ian E. Krop, Dana-Farber Cancer Institute, Boston, MA., Greenson JK; Véronique Diéras, Institut Curie, Paris, France; Nadia Harbeck, University of Munich, Munich, Germany; G. Thomas Budd, Cleveland Clinic, Lerner College of Medicine, Cleveland, OH; Joel K. Greenson, University of Michigan, Ann Arbor, MI; Ellie A. Guardino, Meghna Samant, Nataliya Chernyukhin, and Melanie C. Smitt, Genentech, South San Francisco, CA; and Ian E. Krop, Dana-Farber Cancer Institute, Boston, MA., Guardino AE; Véronique Diéras, Institut Curie, Paris, France; Nadia Harbeck, University of Munich, Munich, Germany; G. Thomas Budd, Cleveland Clinic, Lerner College of Medicine, Cleveland, OH; Joel K. Greenson, University of Michigan, Ann Arbor, MI; Ellie A. Guardino, Meghna Samant, Nataliya Chernyukhin, and Melanie C. Smitt, Genentech, South San Francisco, CA; and Ian E. Krop, Dana-Farber Cancer Institute, Boston, MA., Samant M; Véronique Diéras, Institut Curie, Paris, France; Nadia Harbeck, University of Munich, Munich, Germany; G. Thomas Budd, Cleveland Clinic, Lerner College of Medicine, Cleveland, OH; Joel K. Greenson, University of Michigan, Ann Arbor, MI; Ellie A. Guardino, Meghna Samant, Nataliya Chernyukhin, and Melanie C. Smitt, Genentech, South San Francisco, CA; and Ian E. Krop, Dana-Farber Cancer Institute, Boston, MA., Chernyukhin N; Véronique Diéras, Institut Curie, Paris, France; Nadia Harbeck, University of Munich, Munich, Germany; G. Thomas Budd, Cleveland Clinic, Lerner College of Medicine, Cleveland, OH; Joel K. Greenson, University of Michigan, Ann Arbor, MI; Ellie A. Guardino, Meghna Samant, Nataliya Chernyukhin, and Melanie C. Smitt, Genentech, South San Francisco, CA; and Ian E. Krop, Dana-Farber Cancer Institute, Boston, MA., Smitt MC; Véronique Diéras, Institut Curie, Paris, France; Nadia Harbeck, University of Munich, Munich, Germany; G. Thomas Budd, Cleveland Clinic, Lerner College of Medicine, Cleveland, OH; Joel K. Greenson, University of Michigan, Ann Arbor, MI; Ellie A. Guardino, Meghna Samant, Nataliya Chernyukhin, and Melanie C. Smitt, Genentech, South San Francisco, CA; and Ian E. Krop, Dana-Farber Cancer Institute, Boston, MA., Krop IE; Véronique Diéras, Institut Curie, Paris, France; Nadia Harbeck, University of Munich, Munich, Germany; G. Thomas Budd, Cleveland Clinic, Lerner College of Medicine, Cleveland, OH; Joel K. Greenson, University of Michigan, Ann Arbor, MI; Ellie A. Guardino, Meghna Samant, Nataliya Chernyukhin, and Melanie C. Smitt, Genentech, South San Francisco, CA; and Ian E. Krop, Dana-Farber Cancer Institute, Boston, MA.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2014 Sep 01; Vol. 32 (25), pp. 2750-7. Date of Electronic Publication: 2014 Jul 14.